Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Follow‐up of renal transplant recipients after acute COVID‐19—A prospective cohort single‐center study (CROSBI ID 320613)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Bašić-Jukić, Nikolina ; Jurić, Ivana ; Furić-Čunko, Vesna ; Katalinić, Lea ; Radić, Josipa ; Bošnjak, Zrinka ; Jelaković, Bojan ; Kaštelan, Željko Follow‐up of renal transplant recipients after acute COVID‐19—A prospective cohort single‐center study Immunity, Inflammation and Disease, 9 (2021), 4; 1563-1572. doi: 10.1002/iid3.509

Podaci o odgovornosti

Bašić-Jukić, Nikolina ; Jurić, Ivana ; Furić-Čunko, Vesna ; Katalinić, Lea ; Radić, Josipa ; Bošnjak, Zrinka ; Jelaković, Bojan ; Kaštelan, Željko

engleski

Follow‐up of renal transplant recipients after acute COVID‐19—A prospective cohort single‐center study

Introduction: Although most patients recover within several weeks after acute COVID-19, some of them develop long-lasting clinical symptoms. Renal transplant recipients have an increased mortality risk from COVID-19. We aimed to describe complications occurring after COVID-19 in this group of patients. Methods: A prospective single- center cohort study was conducted at University Hospital Centre Zagreb. Patients with two negative reverse transcriptase-polymerase chain reaction (RT-PCR) tests for SARS-CoV-2 after COVID-19 were eligible for further follow-up at our outpatient clinic. They underwent detailed clinical and laboratory assessments. The primary outcome was the development of complications after COVID-19. Results: Only 11.53% of renal transplant recipients who survived acute COVID-19 were symptomless and free from new-onset laboratory abnormalities during the median follow-up of 64 days (range: 50-76 days). Three patients died from sepsis after discharge from the hospital. In 47 patients (45.2%), clinical complications were present, while 74 patients (71.2%) had one or more laboratory abnormalities. The most common clinical complications included shortness of breath (19.2%), tiredness (11.5%), peripheral neuropathy (7.7%), self-reported cognitive impairments (5.7%), and dry cough (7.7%). Most common laboratory abnormalities included shortened activated partial thromboplastin time (50%), elevated D-dimers (36.5%), elevated fibrinogen (30.16%), and hypogammaglobulinemia (24%). Positive RT-PCR for cytomegalovirus (8.7%), Epstein-Barr virus (26%), or BK virus (16.3%). Multivariate analysis identified the history of diabetes mellitus and eGFR CKD-EPI as predictors for the development of post-COVID clinical complications. Six months after acute COVID-19, elevated D-dimers persisted with normalization of other laboratory parameters. Twenty-nine patients were hospitalized, mostly with several concomitant problems. However, initially reported clinical problems gradually improved in the majority of patients. Conclusion: Post-COVID-19 clinical and laboratory complications are frequent in the renal transplant population, in some of them associated with significant morbidity. All patients recovered from acute COVID-19 should undergo long-term monitoring for evaluation and treatment of complications.

complications ; long-COVID-19 ; mortality ; post-COVID-19 ; renal transplantation ; SARS-CoV-2

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

9 (4)

2021.

1563-1572

objavljeno

2050-4527

10.1002/iid3.509

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost